TxGuard technology is patented to be used for cardiovascular patches, conduit, and TAVR applications. It uses unique materials that are stable against enzymes and can slowly regenerate when implanted. TxGuard material exhibits high resistance to calcification as compared to glutaraldehyde x-linked tissues, which are currently used. TxGuard pulmonary conduit showed no tissue overgrowth, dilation, calcification, or thrombosis when implanted in sheep for a month-long period.
One of the common procedures during complex surgeries consist of soft tissue repair. The pericardium is intended for use as surgical patch material for augmenting the patient’s own tissue to assist in closure following open-heart surgery; Intra-cardiac defects; septal defects and annulus repairs; cardiac and vascular reconstruction and repairs; peripheral vascular reconstruction and repairs; great vessel reconstruction and repairs; and suture-line buttressing. It is also used in urologic surgery, ophthalmology, abdominal hernias, trachea repair.
Every year, approximately 40,000 newborns in the US are affected by Congenital heart disease (CHD). Out of that 2,500 newborns, primarily with conotruncal anomalies, have a defect that requires the use of a substitute, non-native conduit artery to replace structures that are congenitally absent or hypoplastic.
Transcatheter aortic valve replacement (TAVR) is expanding rapidly as an alternative to surgery in newborns with severe symptomatic aortic stenosis (AS) who are at high risks for surgical valve replacement. However, these valves still use tissue material with glutaraldehyde crosslinked pericardium that was developed 50 years ago. We have a new treatment for these tissues that prevent calcification and keeps valves pliable for extended periods. We are looking to partner with a TAVR company to use our materials for the next generation of superior TAVR materials.